Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Facioscapulohumeral Muscular Dystrophy
Sort By
Newest First
1 / 1
1 / 1
Drug Designation
Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Genea Biocells
PR-M06-18-NI-016
Jun 06, 2018
